Nomogram Predicts Melanoma Recurrence Risk After Negative Sentinel Node Biopsy

Share this content:
Current treatment guidelines do not adequately cover what kind of surveillance and treatment should apply to patients with melanoma after a negative sentinel node biopsy.
Current treatment guidelines do not adequately cover what kind of surveillance and treatment should apply to patients with melanoma after a negative sentinel node biopsy.

Measures of ulceration, Breslow thickness, and microsatellitosis in the primary melanoma after a negative sentinel node biopsy (SNB) are predictive of recurrence risk at 1, 2, 5, and 10 years, according to a study published in the Journal of the American Academy of Dermatology.

Current treatment guidelines do not adequately cover what kind of surveillance and treatment should apply to patients with melanoma after a negative SNB, and there is little data on appropriate adjuvant treatments for Stage II patients, even though they are still at risk of recurrence. In the current study, researchers sought to create a nomogram designed to evaluate recurrence risk for patients with a negative SNB based on pathological and clinical characteristics of the primary melanoma. Researchers conducted a retrospective analysis of patients at the Skin Cancer Department of AC Camargo Cancer Center in São Paulo, Brazil, who underwent a SND between 2000 and 2015 (N=1213).

Continue Reading Below

Among those patients, 79.7% (n=967) had a negative SNB. These patients had a mean follow-up of 59.67 months, with 133 melanoma recurrences (13.8%). Forty-five of the 133 recurrences (33.8%) presented with a nodal recurrence, and 35 (26.3%) with a recurrence at the SNB site. Study investigators used the patient data to create a nomogram that assigned points to the 3 most predictive melanoma characteristics (ulceration, Breslow thickness, and microsatellitosis) to determine the probability of survival at 1, 2, 5, and 10 years. 

For example, a hypothetical patient with a primary melanoma tumor that has ulceration (61 points), a 2 mm Breslow thickness (10 points), and does not have microsatellitosis (0 points) would have a total score of 71 points using the nomogram. This can predict that the hypothetical patient has a 90% probability of being recurrence-free after the first year, 77% after year 2, 64% after year 5, and 50% after year 10, with a C-index of 0.749.

Despite the limitations of conducting the analysis at a single treatment center, study investigators concluded they were able to create "a predictive nomogram for melanoma patients after a negative SNB. It is easy to be used and can help both clinicians and patients to provide an individualized follow-up program, as well as to identify high-risk patients who should be considered for adjuvant treatments."

Reference

  1. Bertolli E, Petaccia de Macedo M, Calsavara VF, Lopes Pinto CA, Duprat Neto JP. A nomogram to identify high-risk melanoma patients with a negative sentinel node biopsy [published online November 2, 2018]. J Am Acad Dermatol. doi: 10.1016/j.jaad.2018.10.060

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs